Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From plastics to pathology: The neurodegenerative impact of Bisphenol-A on Alzheimer's disease.

Ageing research reviews·2026
Same author

In silico and in vitro antibacterial investigation of <i>Origanum majorana</i> L. leaves extract against gram-positive and gram-negative bacteria.

In silico pharmacology·2026
Same author

Barriers to Mainstream School Inclusion Among Children with Autism Spectrum Disorder.

Annals of neurosciences·2026
Same author

Integrating HTS and CRISPR/Cas for next-generation nucleic and non-nucleic acid diagnostics.

Molecular genetics and genomics : MGG·2026
Same author

Pharmaco-Epigenomic response of Pimozide is mediated through miR-2909.

Integrative biology : quantitative biosciences from nano to macro·2026
Same author

Decoding neuroinflammation: the critical role of NLRP3 inflammasome in Alzheimer's disease.

Inflammopharmacology·2026

Related Experiment Video

Updated: Jun 10, 2026

Electrophoretic Delivery of &#x3B3;-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Lacosamide, a newer antiepileptic.

Sazal Patyar1, Bikash Medhi

  • 1Department of Pharmacology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.

Neurosciences (Riyadh, Saudi Arabia)
|August 4, 2010
PubMed
Summary

Lacosamide (LCM) is a novel antiepileptic drug that enhances sodium channel slow inactivation and shows neuroprotective effects. Clinical trials confirm its safety and efficacy as an adjunctive treatment for refractory partial seizures.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Lacosamide (LCM) is a newer antiepileptic drug with a unique dual mechanism of action.
  • It selectively enhances slow inactivation of voltage-gated sodium channels and modulates collapsing response mediator protein 2 (CRMP-2).

Purpose of the Study:

  • To review the pharmacological properties, neuroprotective effects, and clinical efficacy of Lacosamide.
  • To explore potential therapeutic applications beyond epilepsy.

Main Methods:

  • Review of in vitro and in vivo animal models demonstrating neuroprotection and analgesic activity.
  • Analysis of safety pharmacology and toxicology studies.
  • Evaluation of clinical trial data for adjunctive treatment of partial seizures.

Main Results:

More Related Videos

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
11:29

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study

Published on: August 15, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Electrophoretic Delivery of &#x3B3;-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
11:29

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study

Published on: August 15, 2025

  • Lacosamide exhibits potent and broad neuroprotective effects in preclinical models.
  • It demonstrates analgesic activity and potential in models of CNS disorders like schizophrenia and anxiety.
  • Clinical trials indicate Lacosamide is a safe, effective, and well-tolerated adjunctive therapy for refractory partial seizures.

Conclusions:

  • Lacosamide is a promising antiepileptic agent with a favorable safety profile.
  • Its neuroprotective and other CNS effects warrant further investigation for expanded therapeutic indications.